| Date |
Title |
| Jul 16, 2026 |
Illumina expands Billion Cell Atlas program with new AI drug developers |
| Jul 9, 2026 |
Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026 |
| Jul 9, 2026 |
Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer |
| Jun 23, 2026 |
Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors |
| Jun 8, 2026 |
Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution |
| May 28, 2026 |
Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research |
| May 28, 2026 |
Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research |
| May 21, 2026 |
David P. King elected to Illumina's Board of Directors |
| May 19, 2026 |
Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact |
| Apr 30, 2026 |
Illumina Reports Financial Results for First Quarter of Fiscal Year 2026 |
| Apr 16, 2026 |
DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows |
| Apr 14, 2026 |
Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease |
| Apr 9, 2026 |
Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026 |
| Apr 2, 2026 |
Illumina Announces Changes to Board of Directors |
| Mar 18, 2026 |
Illumina and Labcorp expand collaboration to broaden access to precision oncology testing |
| Mar 16, 2026 |
Illumina advances preventive genomics through strategic consortium with Veritas Genetics |
| Mar 5, 2026 |
Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering |
| Feb 27, 2026 |
Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida |
| Feb 25, 2026 |
Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics |
| Feb 24, 2026 |
Illumina launches TruPath Genome, setting a new standard in genomic insight |
| Feb 23, 2026 |
Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility |
| Feb 17, 2026 |
Illumina To Webcast Upcoming Investor Conference |
| Feb 5, 2026 |
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025 |
| Feb 3, 2026 |
Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally |
| Jan 30, 2026 |
Illumina completes acquisition of SomaLogic |
| Jan 20, 2026 |
Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology |
| Jan 13, 2026 |
Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery |
| Jan 13, 2026 |
Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 |
| Jan 12, 2026 |
Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026 |
| Jan 8, 2026 |
Illumina Appoints Dr. Eric Green as Chief Medical Officer |
| Jan 6, 2026 |
Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis |